Company intelligence / Profile preview
TocopheRx
Boston, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
TocopheRx was developing a first-in-class oral small molecule FSH agonist intended to replace injectable fertility treatments. As of 2016, the company was in preclinical testing and projected readiness to enter safety trials in humans in 2017. Preclinical safety testing showed safe toxicology, with notable ovarian enlargement observed at high doses in mice, manageable through dose limiting.
- Therapeutic areas
- Endocrinology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Merck Serono (parent company via MS Ventures investment)
Beyond the preview
Go deeper on TocopheRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TocopheRx.